Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.

Frenel JS, Zeghondy J, Guérin-Charbonnel C, Mailliez A, Volant E, Poumeaud F, Patsouris A, Arnedos M, Bailleux C, Cabal J, Galland L, de Nonneville A, Guiu S, Dalenc F, Pistilli B, Bachelot T, Pierga JY, Le Du F, Bocquet F, Larrouquere L, Loirat D.

Open source

DOI: 10.1001/jamanetworkopen.2024.4435
Published: 2024-04-01
Container: JAMA Netw Open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamanetworkopen.2024.4435,
  title = {Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.},
  author = {Frenel JS and  Zeghondy J and  Guérin-Charbonnel C and  Mailliez A and  Volant E and  Poumeaud F and  Patsouris A and  Arnedos M and  Bailleux C and  Cabal J and  Galland L and  de Nonneville A and  Guiu S and  Dalenc F and  Pistilli B and  Bachelot T and  Pierga JY and  Le Du F and  Bocquet F and  Larrouquere L and  Loirat D.},
  year = {2024},
  journal = {JAMA Netw Open},
  doi = {10.1001/jamanetworkopen.2024.4435},
  url = {https://doi.org/10.1001/jamanetworkopen.2024.4435}
}

RIS

TY  - JOUR
TI  - Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
AU  - Frenel JS
AU  -  Zeghondy J
AU  -  Guérin-Charbonnel C
AU  -  Mailliez A
AU  -  Volant E
AU  -  Poumeaud F
AU  -  Patsouris A
AU  -  Arnedos M
AU  -  Bailleux C
AU  -  Cabal J
AU  -  Galland L
AU  -  de Nonneville A
AU  -  Guiu S
AU  -  Dalenc F
AU  -  Pistilli B
AU  -  Bachelot T
AU  -  Pierga JY
AU  -  Le Du F
AU  -  Bocquet F
AU  -  Larrouquere L
AU  -  Loirat D.
PY  - 2024
JO  - JAMA Netw Open
DO  - 10.1001/jamanetworkopen.2024.4435
UR  - https://doi.org/10.1001/jamanetworkopen.2024.4435
ER  -

APA

JS, F., J, Z., C, G., A, M., E, V., F, P., A, P., M, A., C, B., J, C., L, G., A, D. N., S, G., F, D., B, P., T, B., JY, P., F, L. D., F, B., L, L., & D., L. (2024). Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.. JAMA Netw Open. https://doi.org/10.1001/jamanetworkopen.2024.4435

Source records

europe-pmc · retrieved 2026-11-10T11:28:08.169Z
hal · retrieved 2026-11-10T11:28:08.232Z